18-21-5　ⓔ文献

  1. Bohan A, Peter JB: Polymyositis and dermatomyositis (first of two parts). N Engl J Med, 1975; 292: 344–347.

  2. Bohan A, Peter JB: Polymyositis and dermatomyositis (second of two parts). N Engl J Med, 1975; 292: 403–407.

  3. Hoogendijk JE, Amato AA, et al: 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands. Neuromuscul Disord, 2004; 14: 337–345.

  4. Allenbach Y, Mammen AL, et al: Clinico–sero–pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14–16 October 2016. Neuromuscul Disord, 2018; 28: 87–99.

  5. Selva–O’Callaghan A, Pinal–Fernandez I, et al: Classification and management of adult inflammatory myopathies. Lancet Neurol, 2018; 17: 816–828.

  6. Schmidt J: Current classification and management of inflammatory myopathies. J Neuromuscul Dis, 2018; 5:109–129.

  7. Larman HB, Salajeghah M, et al: Cytosolic 5′–nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol, 2013; 73: 408–418.

  8. Pluk H, van Hoeve BJA, et al: Autoantibodies to cytosolic 5′–nucleotidase IA in inclusion body myositis. Ann Neurol, 2013; 73: 397–407.

  9. Greenberg SA: Inclusion body myositis: clinical features and pathogenesis. Nat Rev Rheumatol, 2019; 15: 257–272.